NeuMoDx Molecular12.10.19
NeuMoDx Molecular, a molecular diagnostic company focused on developing testing solutions for hospital and commercial reference laboratory customers, and Sentinel Diagnostics, a company engaged in the development and production of diagnostic kits for Clinical Chemistry, Immunochemistry and Molecular Biology, have partnered to develop multiple diagnostic assays for the NeuMoDx 96 and 288 Molecular Systems.
NeuMoDx Molecular offers solutions that integrate the entire molecular diagnostic process - from extraction to detection or ‘sample to result’ – with the first result available in approximately one hour. These analyzers provide operators with the ability to load up to 288 patient samples in a continuous, random-access workflow resulting in on-demand, high throughput sample processing with a true operator walkaway window of up to eight hours.
Sentinel Diagnostics has more than 35 years of experience in the development and production of IVD products. In Molecular Diagnostics, Sentinel developed STAT-NAT, a proprietary technology able to stabilize the activity of PCR Mix, allowing room temperature transport and storage, performance improvement and long shelf life.
“Sentinel Diagnostics is a leader in developing innovative tests to meet the diagnostic testing needs of the clinical diagnostics laboratory and we are excited to partner with them as we continue to expand the test menu on our fully automated continuous random-access NeuMoDx Molecular systems,” said Jeff Williams, chairman and CEO of NeuMoDx.
Sentinel’s real-time PCR assays will be adapted to the NeuMoDx 96 and 288 Molecular Systems and will incorporate the STAT-NAT technology, which will be specifically optimized for the NeuMoDx Molecular systems. The result of this collaboration will be a broad portfolio of molecular diagnostic assays, providing a wide variety of clinical applications. The new test menu pipeline for the NeuMoDX Molecular systems will include assays to detect and monitor post-transplant infections, parasitic and hospital acquired infections, respiratory infections and for pharmacogenetics applications.
“Today, laboratories worldwide need to increase efficiency and throughput, while continuing to provide high quality results,” said Ugo De Luca, CEO at Sentinel Diagnostics. “Vast experience in IVD development / manufacturing enabled Sentinel to develop STAT-NAT patented technology, and produce lyophilized ready-to-use molecular tests, with high-sensitivity and specificity. In addition, with room temperature transport and storage, STAT-NAT assays are eco-friendly – saving energy and reducing CO2 emissions. The partnership with NeuMoDx Molecular Systems is a win-win for both companies and benefits patients and diagnostic labs worldwide.”
NeuMoDx Molecular offers solutions that integrate the entire molecular diagnostic process - from extraction to detection or ‘sample to result’ – with the first result available in approximately one hour. These analyzers provide operators with the ability to load up to 288 patient samples in a continuous, random-access workflow resulting in on-demand, high throughput sample processing with a true operator walkaway window of up to eight hours.
Sentinel Diagnostics has more than 35 years of experience in the development and production of IVD products. In Molecular Diagnostics, Sentinel developed STAT-NAT, a proprietary technology able to stabilize the activity of PCR Mix, allowing room temperature transport and storage, performance improvement and long shelf life.
“Sentinel Diagnostics is a leader in developing innovative tests to meet the diagnostic testing needs of the clinical diagnostics laboratory and we are excited to partner with them as we continue to expand the test menu on our fully automated continuous random-access NeuMoDx Molecular systems,” said Jeff Williams, chairman and CEO of NeuMoDx.
Sentinel’s real-time PCR assays will be adapted to the NeuMoDx 96 and 288 Molecular Systems and will incorporate the STAT-NAT technology, which will be specifically optimized for the NeuMoDx Molecular systems. The result of this collaboration will be a broad portfolio of molecular diagnostic assays, providing a wide variety of clinical applications. The new test menu pipeline for the NeuMoDX Molecular systems will include assays to detect and monitor post-transplant infections, parasitic and hospital acquired infections, respiratory infections and for pharmacogenetics applications.
“Today, laboratories worldwide need to increase efficiency and throughput, while continuing to provide high quality results,” said Ugo De Luca, CEO at Sentinel Diagnostics. “Vast experience in IVD development / manufacturing enabled Sentinel to develop STAT-NAT patented technology, and produce lyophilized ready-to-use molecular tests, with high-sensitivity and specificity. In addition, with room temperature transport and storage, STAT-NAT assays are eco-friendly – saving energy and reducing CO2 emissions. The partnership with NeuMoDx Molecular Systems is a win-win for both companies and benefits patients and diagnostic labs worldwide.”
